Consistent with our findings in this monkey study, incremental increases in exogenous basal insulin therapy in humans with T2D without additional postprandial insulin administration, but with accompanying daily glucose monitoring, achieve clinically acceptable glycemic targets while mostly eliminating hypoglycemic episodes [55,74]. The gene discussed is INS; the disease is type 2 diabetes mellitus.